Poland· PL-100425759
Abacavir Accord
A abacavir product containing abacavirum, registered in Poland by Accord Healthcare Polska Sp. z o.o.. The same ATC class is registered in 16 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Abacavir is registered in 16 of 19 countries.
Countries holding a registration under ATC J05AF06 (abacavir), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 10 of them publish a price we can compare per daily dose
Abacavir · ATC J05AF06
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of abacavir costs, country by country.
Normalised to the WHO defined daily dose (0.6 g), the median price runs from $3.98 in France to $9.36 in Switzerland — a ×2.3 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Abacavir · price per daily dose (0.6 g)
USD · FX 28 Sept 2026
- CH Switzerland$9.36
- FR France$3.98
The record
At a glance
URPL (Poland)- Active substance
- Abacavirum
- Manufacturer
- Accord Healthcare Polska Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- J05AF06
- ATC class
- Abacavir
- Defined daily dose
- 0.6 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 8
- gtin05909991439279
- gtin05909991439286
- gtin05909991439293
- gtin05909991439309
- gtin05909991439316
- gtin05909991439323
- gtin05909991439330
- gtin05909991439347
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
131 interactions on record for abacavir.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Abacavir · interactions on record
131 records
- 4 severe
- 23 moderate
- 6 minor
- 96 info
Most severe, free to view
- LeflunomidL04AA13severe
- TeriflunomidL04AA31severe
- LeflunomideL04AK01severe
- TeriflunomideL04AK02severe
2 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Abacavir in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesAbacavirAurobindo Pharma Limited
- SpainABACAVIR ACCORD 300 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGAccord Healthcare S.L.U.
- FinlandAbacavir AccordAccord Healthcare B.V.
- FranceABACAVIR ARROW 300 mg, comprimé pelliculé sécableARROW GENERIQUES
- BelgiumAbacavir Sandoz 300 mgSandoz
- NetherlandsAbacavir Accord 300 mg, filmomhulde tablettenAccord Healthcare B.V.
- SwedenAbacavir Accord 300 mg Filmdragerad tablettAccord Healthcare B.V.
- IrelandZiagen 300mg Film-coated tableViiV Healthcare BV
Authorised across Europe · EMA
The same active substance is authorised in 11 EEA countries. Names it is sold under:
- Spain · Abacavir Tarbis
- Finland · Abacavir Accord
- France · Abacavir Arrow, Abacavir Sandoz
- United Kingdom (Northern Ireland) · Abacavir Milpharm, Abacavir Mylan
- Iceland · Ziagen
- Italy · Abacavir Mylan
- Liechtenstein · Ziagen
- Netherlands · Abacavir Accord, Abacavir Sandoz
- Norway · Ziagen
- Portugal · Abacavir Farmoz, Abacavir Generis
- Romania · Abacavir Aurobindo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/86c47519-2073-4ce0-8396-062598a84b3f GET /v1/drugs/86c47519-2073-4ce0-8396-062598a84b3f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "300 mg",
"packaging": "05909991439279 ¦ Rpz ¦ 137741\n30 tabl.\n05909991439286 ¦ Rpz ¦ 137742\n30 tabl.\n05909991439293 ¦ Rpz ¦ 137743\n60 tabl.\n05909991439309 ¦ Rpz ¦ 137744\n60 tabl.\n05909991439316 ¦ Rpz ¦ 137745\n90 tabl.\n05909991439323 ¦ Rpz ¦ 137746\n90 tabl.\n05909991439330 ¦ Rpz ¦ 137747\n120 tabl.\n05909991439347 ¦ Rpz ¦ 137748\n120 tabl.",
"substance": "Abacavirum 300 mg",
"common_name": "Abacavirum",
"pl_product_id": "100425759",
"pozwolenie_nr": "26073",
"auth_procedure": "MRP",
"authorisation_validity": "2025-01-30"
}See everything about abacavir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.